CD229 Protein - ACROBiosystems

Home
Products

products by category

Recombinant proteins
GMP Grade CytokinesNew Fc receptor proteins FcRn Proteins IgG Fc Proteins (Isotype Control) CGT development solutions New Targets of CAR-T cell therapy New Generation Tools for CAR DetectionStar Staining FDA DMF filed proteins Multi-pass TpsHot Immune checkpoint proteins ADC targets BsAb targets TME pathway targets CytokinesHot Enzymes Llama IgG Fc fusion protein Biosimilar drug targets Biomarkers & CD antigens All recombinant proteins

Antibodies
Anti-idiotypic antibody Anti-FMC63 mAb Neutralizing antibodies
Kits/Beads
Pre-coupling magnetic beads Inhinitor screening kits ELISA Assay Kits for Quantitative analysis of therapeutic antibodies in serum
Supports on COVID-19 R&DHot
SARS-CoV-2 related products SARS-CoV-2 mutant products SARS-CoV-2 related kits Reagents for vaccine development Reagents for diagnostic development

Featured products

Pre-labeled proteins
New Generation Tools for CAR DetectionStar Staining Biotinylated protein collection FITC & PE labeled proteins
Full-length multi-pass TpsHot
Multi-pass Tps Claudin 18.2 GPCRs CD20 proteins
Proteins for Neuroscience
Proteins for Neuroscience New
Cytokines
ActiveMax Cytokines Hot Promising Therapeutic Targets Hot

Hot targets
CD19 BCMA CD3 proteins IL-2 receptors IL-6 and IL-6 Receptor Proteins Claudin 18.2 GPCRs CD20 proteins CD39/CD73 proteins B7 families TNFSF proteins VEGF proteins PD1 proteins TIGIT Siglec-15 proteins Integrin CD24&siglec-10
Services

Innovation Lab
SPR /BLI analytical serviceNew Enzyme-Linked Immunosorbent Assay (ELISA) Service New Meso Scale Discovery (MSD) ServiceNew Anti-Idiotypic Antibody Development ServiceNew Pseudovirus Neutralization Assay ServiceNew

Licensing Opportunities
Target 4-1BB monoclonal antibody New PD-1/CD80 bispecific antibodyNew Antagonizing TSP1/CD36 Polypeptide Blocking the activation of TGF-β1New Anti-PD-L1 / TIGIT bispecific antibodyNew TIGIT-Fc proteinNew Novel small molecule drug for cancer cachexiaNew
Supports

How to Order Shipping & Payments Global Distributors Testimonials FAQs Download COA
Applications

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression Claudin18.2-VLP：designed for CAR detection SPR & BLI：Binding activity assay SEC-MALS: Aggregation state and purity
News

News Insights Promotions Exhibitions
Resources

Download Brochures Download E-resources Download COA
ACROBiosystems

About Us Join Us Contact Us

CD229


CD9-H82E6	Human	Biotinylated Human CD229 / SLAMF3 Protein, His,Avitag™
CD9-H52H6	Human	Human CD229 / SLAMF3 Protein, His Tag

Cat. No.

Species

Product Description

Structure

Purity

Feature

CD9-H82E6

Human

Biotinylated Human CD229 / SLAMF3 Protein, His,Avitag™

CD9-H52H6

Human

Human CD229 / SLAMF3 Protein, His Tag

Part of Bioactivity data

CD9-H52H6-ELISA

Immobilized Human CD229, His Tag (Cat. No. CD9-H52H6) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD229, His,Avitag (Cat. No. CD9-H82E6) with a linear range of 0.039-2.5 μg/mL (QC tested).

Protocol

CD9-H82E6-ELISA

Protocol

Synonym Name

SLAMF3,LY9,Ly-9,hly9,Ly9

Background

CD229, also known as Ly9 and SLAMF3, is a 120 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. Signaling lymphocyte activation molecule (SLAM) family receptors are critically involved in modulating innate and adaptive immune responses. CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells. Homophilic binding between CD229 molecules is mediated by the N-terminal Ig-like domain.

Clinical and Translational Updates